Us2.ai receives FDA clearance for Us2.v2,transforming…

DURHAM, N.C. -- January 6, 2021 -- Ribometrix, Inc., today announced a strategic collaboration with Genentech, a member of the Roche Group, to discover and develop novel RNA-targeted small molecule therapeutics against several targets.

Ribometrix is focused on leveraging its RNA structural expertise and analytical capabilities to make the vast landscape of RNA, which is involved in a wide variety of disease processes, accessible to small molecule therapeutics. Ribometrix’s platform uses multiple specialized technologies, including world-leading structural analytic capabilities, to identify 3D motifs in RNA molecules and then design small molecule candidates that bind to these motifs to produce a therapeutic effect.

BOSTON & DURHAM, NC, September 30, 2019 -- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and RNA therapeutics developer Ribometrix, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The collaboration will combine Ribometrix’s proprietary discovery platform for identifying and optimizing small molecule therapeutics that modulate RNA function by targeting three-dimensional (3D) RNA structures with Vertex’s scientific, clinical and regulatory capabilities for up to three therapeutic programs, including one ongoing discovery program from Ribometrix.

DURHAM, NC, September 27, 2019 -- Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, today announced $7.8 million in additional funding from existing investors, the Dementia Discovery Fund and Illumina Ventures. Ribometrix also announced the appointment of Mike Clayman, M.D., as chairman of the board of directors. The new funding will support the continued development of the Ribometrix discovery platform, which uses sophisticated structural analysis and proprietary assays to identify ligands that bind to highly structured pockets in therapeutically compelling RNAs to modulate protein expression. Ribometrix’s approach is designed to enable the discovery of selective, orally bioavailable, RNA-binding small molecules with broad tissue distribution and bioavailability.

DURHAM, NC -- November 13, 2018 -- Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, announced today that it has completed a $30 million Series A financing to advance its discovery platform and internal pipeline of novel small molecule drugs that directly modulate RNA activity, as well as expand its team and business development activity. The round was led by M Ventures, with participation of new investors Amgen Ventures, Pappas Capital and Illumina Ventures. Founding investors SV Health Investors, AbbVie Ventures, Hatteras Venture Partners, MP Healthcare Venture Management, the Dementia Discovery Fund and Alexandria Venture Investments also joined the round. Hakan Goker, Ph.D., Senior Investment Director of M Ventures, will join the board as a non-executive director with immediate effect.